TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04912063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet
Study: NCT05746143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg
Description: two days preoperatively and five days postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two days preoperatively and five days postoperatively
Study: NCT05361408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, once
Description: Intravenous infusion of 5mg zoledronic acid, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, twice
Description: Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
Study: NCT06024148

Intervention type: OTHER
Intervention: phone survey
Description: patients complete a 10-minute telephone questionnaire on their osteoporosis management
Study: NCT06334146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tap dance program
Description: Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
Study: NCT05254509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy +Virtual Reality
Description: The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
Study: NCT06232499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Laser Irradiation of Blood
Description: The different color lights for Intravenous Laser Irradiation of Blood are red light at 808nm and blue light at 415nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Laser Irradiation of Blood
Description: The different color lights for Intravenous Laser Irradiation of Blood are red light at 808nm and blue light at 415nm
Study: NCT04732117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
Study: NCT06431373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib PO QD
Description: Brepocitinib PO QD
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments.
Study: NCT06423261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 Recombinant Peptide Inhalation Solution
Description: Inhalation administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 Recombinant Peptide Inhalation Solution
Description: Inhalation administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhalation administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhalation administration
Study: NCT05740280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCP-NI
Description: 20 mg/mL iCP-NI solution for intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for intravenous injection
Study: NCT05866523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Based Inpatient ARTAS
Description: Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subject admitted and seen by routine inpatient medical service.
Study: NCT06431373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO QD
Description: Placebo PO QD
Study: NCT06692023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study: NCT05598164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A.
Study: NCT06692023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study: NCT05109520

Intervention type: DRUG
Intervention: Insulin Glargine 300 UNT/ML [Toujeo]
Description: Switch during standard routine care to Gla-300.
Study: NCT06692959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 vaccine IMU-201 (PD1-Vaxx)
Description: Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
Study: NCT06723821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation group
Description: During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromodulation sham group
Description: During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
Study: NCT06157060

Intervention type: DIAGNOSTIC_TEST
Intervention: circulating tumor DNA
Description: blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
Study: NCT05741593

Intervention type: OTHER
Intervention: Analysis of the verbatim from the transcription of the recorded interviews.
Description: recorded semi-structured interviews between the patients and the pharmacist
Study: NCT06726889

Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Patient will not receive any additional interventions
Study: NCT05612022

Intervention type: PROCEDURE
Intervention: AVF creation
Description: AVF is surgically created in the forearm by an anastomosis between a vein and an artery

Intervention type: PROCEDURE
Intervention: AVG creation
Description: Surgery is done using an artificial plastic tube that connects an artery to a vein
Study: NCT05039853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive task-based intervention
Description: Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation +/- Boosters

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo activity
Description: Listening to a pod-cast on a smart-device for approximately 15 minutes.
Study: NCT04606914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine (MIRV; IMGN853)
Description: Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
Study: NCT05436834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.815
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.815
Description: Sterile liquid for injection
Study: NCT06242678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS trial lead
Description: placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome
Study: NCT05660291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating
Description: Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating
Description: Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
Study: NCT05251311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Risk Screening Tool
Description: Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Resource Map
Description: All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Resource Map
Description: All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Menu
Description: Participants randomized to this experimental arm will receive a social resource menu tool, which assess desire for social resources.
Study: NCT05177211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
Study: NCT04942327

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
Study: NCT05679557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative geriatric assessment and intervention
Description: The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
Study: NCT06048497

Intervention type: DEVICE
Intervention: Corrected carotid flow time measurement guided fluid preload
Description: Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
Study: NCT05438771

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper
Description: mouth wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: mouth wash
Study: NCT05407766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSSM-001
Description: Single injection of OSSM-001 at dose of 100M or 300M cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSSM-001
Description: Single injection of OSSM-001 at dose of 100M or 300M cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of placebo (saline)
Study: NCT05157997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab Antibody Cocktail
Description: The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
Study: NCT05434754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Tool
Description: text messaging algorithm
Study: NCT05642975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups
Study: NCT05253651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given by mouth (orally) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 5mg/kg given by IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study: NCT05938465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXE-346
Description: EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXE-346
Description: EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXE-346
Description: EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains excipients maltose and silicon dioxide.
Study: NCT05253651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levoleucovorin
Description: 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levoleucovorin
Description: 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Study: NCT04869514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spinal manipulation
Description: intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation